Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm

Table 2 Sorafenib for recurrent hepatocellular carcinoma after liver transplantation

	No. (SFN/BSC)	Duration after LT (mo)	mTOR inhibitor (yes/no)	Response rate (% complete/partial/stable)	Median OS (mo)	Time to progression (mo)	Drug toxicity leading to
							Dose reduction (% patient)	Discontinuation (% patient)
Meta-analysis
Mancuso et al[42],2015	113	13.6	-	0/4.8/44.4	10.5	5.6	42.8	31.9
Retrospective cohort
Sposito et al[43], 2013	15/24	38.1/15.72	7/8	-	21.3/11.82	8.8/10.2	53.3	4.1
De'Angelis et al[45], 2016	15/18	18	7/8	0/26.6/46.8	41.4/19.12	-	53.3	13.3
Pinero et al[46], 2016	10/10	-	7/3	-	20/12.5	5/32	90	20
Case series
Yoon et al[47], 2010	13	12.3	1/12	0/0/46	5.4	2.9	30.7	0
Kim et al[48],2010	9	12.4	7/2	11/0/44	-1	-	-	0
Vitale et al[49], 2012	10	7	10/0	0/20/60	18	8	40	30
Gomez-Martin et al[50], 2012	31	22.6	31/0	0/3.8/50	19.3	6.77	25.8	-
Weinmann et al[51], 2012	11	37.5	9/2	0/0/36	20.1	4.1	73	18
Sotiropoulos et al[52], 2012	14	8	14/0	-	25	-	33	17
Zavaglia et al[44], 2013	11	12	7/4	0/18/9	5	17	90	-

¹Median survival not reached;

²Statistically significant. SFN: Sorafenib; BSC: Best supportive care; LT: Liver transplant; mTOR: Mammalian target of rapamycin; OS: Overall survival.